Earnings ·
Reports Q3 revenue of $342M, raises full-year DAYBUE sales guidance to $505–$520 million
ACADAcadia Pharmaceuticals Inc
Acadia Pharmaceuticals reported third-quarter GAAP total revenues of $342 million, a 22% increase year-over-year. Net product sales for NUPLAZID reached $202 million, up 12% on a non-GAAP adjusted basis, while DAYBUE net sales rose 39% to $140 million, driven by strong uptake of the STIX formulation. The company raised its full-year 2026 DAYBUE global net product sales guidance to $505–$520 million and narrowed its NUPLAZID range to $760–$775 million. Additionally, Acadia announced Phase 3-enabling results for remlifanserin in Alzheimer’s disease psychosis and received FDA Fast Track designation for the drug in Lewy body dementia psychosis. The company operates in the pharmaceutical industry, developing and commercializing treatments for neurological and rare diseases.